Shire PLC (SHPG)

164.03
3.81 2.38
NASDAQ : Health Care
Prev Close 160.22
Open 160.27
Day Low/High 159.84 / 165.27
52 Wk Low/High 147.60 / 270.63
Volume 2.29M
Avg Volume 1.18M
Exchange NASDAQ
Shares Outstanding 302.66M
Market Cap 49.27B
EPS 1.30
P/E Ratio 44.24
Div & Yield 1.54 (0.90%)

Latest News

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Big gains could be ahead for investors willing to stick with the stock, according to one firm.

Biotech Movers: Shire, Bellicum, Organovo

Biotech Movers: Shire, Bellicum, Organovo

Shire, Bellicum Pharmaceuticals and Organovo Holdings were among the biotech stock movers in premarket trading on June 22.

Shire Plc: U.S. FDA Approves Mydayis[TM] (Mixed Salts Of A Single-Entity Amphetamine Product) - A New Once-Daily Option For ADHD Symptom Control In Patients 13 Years And Older

Mydayis demonstrated improvements lasting up to 16 hours post-dose, beginning at 2 or 4 hours post-administration, compared to placebo, in total score on a skill-adjusted math test that measures attention in ADHD

The Activist Who Pushed Whole Foods Into the Arms of Amazon Could Target These Companies Next

The Activist Who Pushed Whole Foods Into the Arms of Amazon Could Target These Companies Next

Here are the activist investor's next potential targets.

Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals

Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals

Plus more from the biotechnology world on Wednesday, June 7.

Biotech Movers: Fast Track Designation Sends Sage Shares Higher

Biotech Movers: Fast Track Designation Sends Sage Shares Higher

Sage Therapeutics, Incyte and Shire were among the biotech movers in premarket trading on Thursday.

Shire Stock Rises Premarket on Positive Phase 3 Results for Angiodema Treatment

Shire Stock Rises Premarket on Positive Phase 3 Results for Angiodema Treatment

The study tested the drug on patients aged 12 years and older for 26 weeks.

Shire Continues 20-Year Commitment To ADHD With New Research At 2017 Annual Meeting Of American Psychiatric Association

Latest Research Supports Greater Understanding of the Evolving Needs of Adults with ADHD

Shire Granted EU Conditional Marketing Authorisation For Natpar[®¿] (Parathyroid Hormone) For The Treatment Of Patients With Chronic Hypoparathyroidism

Natpar is the first and only licensed recombinant human parathyroid hormone therapy for chronic hypoparathyroidism

Shire Launches #PIPostsThanks Social Campaign To Raise Awareness Of Primary Immunodeficiency (PI)

Shire launches campaign to raise global awareness during World PI Week

What to Expect From European Pharmaceuticals' First Quarter Results

What to Expect From European Pharmaceuticals' First Quarter Results

New drug launches and late stage trials will be under the microscope as eight European pharmaceuticals companies report Q1 earnings starting next week.

PatientsLikeMe And Shire Pharmaceuticals Collaborate To Study Rare Genetic Diseases

PatientsLikeMe and Shire plc (LSE: SHP, NASDAQ: SHPG) have announced a new collaboration that will support the development of a patient-centered, real world health learning system that expands understanding of...

European Stocks Mixed as Frankfurt Rises, Paris Falls

European Stocks Mixed as Frankfurt Rises, Paris Falls

The Dax rose following a strong performance from the automotive sector, but both London and Paris slumped.

CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative To Patients' Previous Immunoglobulin Therapy

Shire data presentations at AAAAI 2017 reinforce the efficacy, safety, and tolerability of CUVITRU for primary immunodeficiency patients